Fig. 3
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-021-08579-w/MediaObjects/12885_2021_8579_Fig3_HTML.png)
Regorafenib and panobinostat induce tumor growth inhibition in vivo. Mice xenografted with A, VAESBJ tumors and A204 tumors were treated daily with 30 mg/kg regorafenib p.o.; graph represents means ± SEM of N = 8 to 9 tumors per group. Statistical analysis in both experiments was performed using the nonparametric Mann-Whitney test; p < 0.001 each. B Animals bearing VAESBJ tumors were treated with 8 and 12 mg/kg panobinostat i.p. three times per week; graph represents means ± SEM of N = 11 to 16 tumors per group. Statistical analysis was performed using the nonparametric Kruskal-Wallis test; p < 0.05 for 8 mg/kg and p < 0.0005 for 12 mg/kg. C ERK and AKT activation in tumors harvested after 24 h of a single dose of 8 and 12 mg/kg panobinostat i.p. are shown by Western blot